AzTrials
AzTrials

Depression Anxiety DisorderNCT03607708

Alternative Treatments To Prevent Cognitive Decline in Older Adults With Depression and Anxiety

A study testing Mindfulness-Based Cognitive Therapy (MBCT) and Health Enhancement Program (HEP) in people with Depression Anxiety Disorder, run by Lady Davis Institute at 2 sites in Canada.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

Major depression and anxiety disorders are leading causes of disability worldwide. These mental disorders deeply impact social functioning and physical health in more than 300,000-600,000 Canadians over the age of 60. Read more about this study

Who is it for?
Ages 60 to 85 years
Conditions the study is for
Depression Anxiety Disorder
What is being tested?
Mindfulness-Based Cognitive Therapy (MBCT) and Health Enhancement Program (HEP)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
2 sitesCanada
Study dates
10 Jun 2019to 20 Dec 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients will be >60 years of age presenting with clinically meaningful symptoms of depression or anxiety (PHQ-9 or GAD-7 scores ≥10).
  • Participants will be willing and able to attend at least 75% of weekly HEP or MBCT sessions.
  • Have sufficient hearing to follow verbal instructions;
  • Have adequate understanding of English and/or French.
  • Able to sit for 20-25 minutes without discomfort.

Who cannot join

  • Inability to provide informed consent.
  • Clinical evidence of dementia as defined by the Mini-Cog; a lifetime diagnosis of bipolar I or II disorder or primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder).
  • High acute risk of suicide (e.g., active suicidal ideation and/or current/recent intent or plan).
  • Severe personality disorder, that will interfere with their ability to function in a group setting.
  • Active substance use; non-correctable.
  • Clinically significant sensory impairment.
Show all 10Show fewer
  • Diagnosed Intellectual Deficiency (e.g. Childhood Mental Retardation, Autism)
  • Acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months; having a terminal medical diagnosis with prognosis of less than 12 months.
  • Currently practicing any form of meditation on a regular basis.
  • Unwilling to remain on the same psychotropic medications including dosage for the first 8 weeks of the study

Trial locations and contacts

2 sites in 1 country.

Canada2 sites
  • Lady David Institute

    Montreal, Quebec, H3T 1E2

  • Douglas Mental Health University Institute

    Montreal, Quebec, H4H 1R3

Other trials in Canada

About this study

Major depression and anxiety disorders are leading causes of disability worldwide. These mental disorders deeply impact social functioning and physical health in more than 300,000-600,000 Canadians over the age of 60. Depressed and anxious older adults have a 2-3 times increased risk of developing dementia and cognitive decline.

Mindfulness-based cognitive therapy (MBCT) is a group meditation intervention that has been beneficial in treating depression and anxiety in younger adults. Our research group has experience conducting clinical trials of MBCT in older adults with depression and anxiety. Meditation therapies may prevent cognitive decline, but no previous study has examined this with MBCT.

Read more

In this 8-week clinical trial, Investigators are examining whether MBCT can strengthen the structural and functional integrity of brain networks and improve cognitive resilience in vulnerable depressed and anxious older adults. Investigators will also examine whether MBCT can improve depression, anxiety symptoms, disability, and quality of life in patients.

Investigators will conduct a pilot randomized controlled trial (RCT), comparing Mindfulness-Based Cognitive Therapy (MBCT; n=15) versus a Health Enhancement Program (HEP; n=15) active control in 30 older patients (>60) with depression or anxiety. Participants will be blinded to the treatment hypothesis while investigators and raters will be additionally blinded to group assignment. Both MBCT and HEP will be taught in weekly sessions over 8 weeks in similar sized groups (4-10 participants).

Investigators will measure the effect of these interventions on brain network function and structure using magnetic resonance imaging at baseline and 8-week timepoints. Investigators will also assess cognitive functioning and a range of clinical symptoms/quality of life measures at baseline, 8-week and 6-month follow-up.

Investigators anticipate that this project will improve quality of life in depressed and anxious older adults by enhancing brain resilience, cognitive function, and general mental health. This project will provides essential pilot data for a longer-term definitive neuroimaging trial of MBCT to assess the potential of this intervention to prevent cognitive decline and dementia in older adults.

Read the detailed description

Context - Review of Literature

Depression and anxiety are common in older adults affecting 300,000-600,000 Canadian seniors annually1. About 30% of patients aged ≥60 suffering from these conditions have cognitive dysfunction across several domains 2,3, and an episode of depression or anxiety in this population increases the odds of developing dementia by two-fold4-6. Cognitive impairment and dementia are major causes of disability and dependency among older people worldwide. These conditions confer poor quality of life and place people in an extremely vulnerable condition7.

Adequate treatment of a depressive/anxiety episode can improve short- and longer-term cognition in executive, language, memory, and processing speed domains8. Because depression and anxiety in late-life are reversible to a certain extent and they are important risk factors for subsequent cognitive decline; improving these conditions can ultimately improve quality of life, lengthen the independent living of vulnerable people, reduces stress and caregiver burden. Unfortunately, existing pharmacotherapy treatments for late-life depression and anxiety have limited effectiveness (50-60% of patients are treatment-resistant), are poorly tolerated, and access is difficult due to the absence of trained personnel. Additionally, there are long waiting lists (up to 12 months) in most Canadian provinces and interventions are administered one-on-one, which is costly for the health system9. Thus, there is an urgent need for novel treatments for late-life depression and anxiety that can also improve cognition and even potentially prevent dementia in the longer-term.

Mindfulness-based cognitive therapy (MBCT) is a group intervention that teaches mindfulness meditation (non-judgemental awareness of the present moment)10. MBCT is scalable, accessible, cost efficient, and has been shown to decrease symptoms of depression, anxiety and other psychiatric disorders11. Additionally, MBCT is associated with improved quality of life 12, disability, caregiver burden and stress13. Studies conducted by our own group have found that mindfulness meditation is feasible and well-tolerated in older patients suffering from depression and anxiety14. While the neural mechanisms of MBCT are not fully understood, previous work in younger adults has shown that this intervention increases grey matter density in the brain's hippocampus, known to be involved in learning, memory and stress15. Moreover, long-term meditation practitioners displayed decreased age-related degeneration of the hippocampus16 These findings are relevant because decreased hippocampal volume17,18 and brain functional connectivity (default mode network)19 are commonly found in depressed patients. Additionally, these findings are also observed early in Alzheimer's disease and are associated with cognitive decline20.

Study Purpose and Rationale

Despite all this evidence, it remains unknown whether MBCT can strengthen brain networks, increase brain volume, and bolster cognition in depressed and anxious older adults. To our knowledge, previous mindfulness studies assessing cognition in older adults have not used MBCT nor have used neuroimaging techniques in depressed and anxious participants. Cognitive assessments in previous studies were not sensitive enough and did not use an appropriate active control group.

Thus, to address these issues, Investigators will conduct a randomized controlled trial (RCT) in late-life depression and anxiety using a standardized MBCT intervention, an appropriate active control group, a more sensitive neurocognitive test battery and the use of neuroimaging methods. In this pilot neuroimaging study, Investigators wish to assess the effects of a standard Mindfulness-Based Cognitive Therapy (MBCT) compared to an active control, Health Enhancement Program (HEP), on a number of clinical and biologically relevant outcomes, with a focus on structural and functional integrity of the default-mode network.

Being tested
Mindfulness-Based Cognitive Therapy (MBCT), Health Enhancement Program (HEP)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mindfulness-Based Cognitive Therapy (MBCT)Other

    The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).

  • Health Enhancement Program (HEP)Other

    Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.

Study groups in NCT03607708
Study groupRoleWhat they receive
Mindfulness-Based Cognitive Therapy (MBCT)ExperimentalThe MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
Receives: Other: Mindfulness-Based Cognitive Therapy (MBCT)
Health Enhancement Program (HEP)Active comparatorHealth Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
Receives: Other: Health Enhancement Program (HEP)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in functional connectivity (rs-fMRI) from baseline to 8- week follow -up

    Using an 8- week RCT, assess the effects of MBCT (compared to an active control condition) on functional integrity of key default- mode network (DMN) nodes using functional connectivity measured by resting-state fMRI,

    Hypothesis . Compared to HEP controls, MBCT- treated patients will show larger increases from baseline to 8- week follow -up in 1) functional connectivity between regions implicated in the DMN

    Measured: Baseline and 8 weeks

  2. Structural Volume Change using structural sMRI from baseline to 8- week follow -up

    Using an 8- week RCT, assess the effects of MBCT (compared to an active control condition) on changes in changes Structural Volume

    Investigators hypothesis : Compared to HEP controls, MBCT- treated patients will show volume increase from baseline to 8- week follow -up in the bilateral hippocampal and posterior cingulate cortex nodes of the DMN,

    Measured: Baseline and 8 weeks

  3. Changes in Glutathione measured by magnetic resonance spectroscopy(MRS) from baseline to 8- week follow -up

    Increase in levels of Glutathione from baseline to 8- week follow -up in key mood regulating brain areas of the DMN (ventro-medial prefrontal cortex).

    Measured: Baseline and 8 weeks

Secondary outcomes (1)
  1. Improvements in cognitive functio

    Using a 8-week RCT, assess whether MBCT is associated with improvements in cognitive function (better attention and processing speed) at 8-week follow-up. Hypothesis 2 . Compared to HEP controls, MBCT-treated patients will show greater improvements on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) from baseline to 8-week follow-up.

    Measured: Baseline and 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2018
  2. Study start10 Jun 2019
  3. Primary completion20 Dec 2021
  4. Study completion20 Dec 2026 (estimated)

Why it stopped: COVID-19

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
RCT
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03607708
Sponsor's protocol ID
LadyDI
Status last verified
Apr 2025
First submitted
11 Jul 2018
Last updated
25 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Thomas Z, Novak M, Platas SGT, Gautier M, Holgin AP, Fox R, Segal M, Looper KJ, Lipman M, Selchen S, Mucsi I, Herrmann N, Rej S. Brief Mindfulness Meditation for Depression and Anxiety Symptoms in Patients Undergoing Hemodialysis: A Pilot Feasibility Study. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2008-2015. doi: 10.2215/CJN.03900417. Epub 2017 Oct 12.

    PubMed 29025788

Questions about this trial

What is this clinical trial studying?

A study testing Mindfulness-Based Cognitive Therapy (MBCT) and Health Enhancement Program (HEP) in people with Depression Anxiety Disorder, run by Lady Davis Institute at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 25 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in functional connectivity (rs-fMRI) from baseline to 8- week follow -up (time frame: Baseline and 8 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03607708, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in